Natera Inc (NTRA) Stake Lessened by Spark Investment Management LLC

Spark Investment Management LLC decreased its holdings in shares of Natera Inc (NASDAQ:NTRA) by 48.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 62,700 shares of the medical research company’s stock after selling 58,500 shares during the period. Spark Investment Management LLC’s holdings in Natera were worth $1,292,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Squarepoint Ops LLC lifted its position in shares of Natera by 47.2% during the 4th quarter. Squarepoint Ops LLC now owns 149,160 shares of the medical research company’s stock valued at $2,082,000 after buying an additional 47,860 shares in the last quarter. Tygh Capital Management Inc. raised its stake in Natera by 18.0% in the 4th quarter. Tygh Capital Management Inc. now owns 414,726 shares of the medical research company’s stock valued at $5,790,000 after purchasing an additional 63,155 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Natera by 121.3% in the 1st quarter. Perkins Capital Management Inc. now owns 129,900 shares of the medical research company’s stock valued at $2,679,000 after purchasing an additional 71,200 shares during the last quarter. Vanguard Group Inc. raised its stake in Natera by 28.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after purchasing an additional 808,976 shares during the last quarter. Finally, RMB Capital Management LLC acquired a new position in Natera in the 4th quarter valued at $1,017,000. Hedge funds and other institutional investors own 87.45% of the company’s stock.

In related news, CFO Michael Burkes Brophy sold 3,192 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total transaction of $51,072.00. Following the completion of the transaction, the chief financial officer now directly owns 13,422 shares in the company, valued at approximately $214,752. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 23,356 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $20.51, for a total value of $479,031.56. Following the transaction, the insider now owns 294,758 shares of the company’s stock, valued at $6,045,486.58. The disclosure for this sale can be found here. Insiders have sold a total of 351,313 shares of company stock valued at $7,132,873 over the last 90 days. 9.29% of the stock is currently owned by company insiders.



Several research analysts recently commented on NTRA shares. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a research note on Saturday, March 2nd. BidaskClub downgraded Natera from a “sell” rating to a “strong sell” rating in a research note on Friday, March 1st. Finally, Canaccord Genuity reissued a “buy” rating and issued a $27.00 price objective on shares of Natera in a research note on Sunday, April 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.13.

Shares of NTRA opened at $23.52 on Wednesday. Natera Inc has a 52-week low of $11.08 and a 52-week high of $29.62. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -10.94 and a beta of 1.80. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.99.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The business had revenue of $66.82 million during the quarter, compared to analysts’ expectations of $66.40 million. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. On average, sell-side analysts forecast that Natera Inc will post -2.17 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2019/05/22/natera-inc-ntra-stake-lessened-by-spark-investment-management-llc.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Why is cost of goods sold important?

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.